Canada markets open in 1 hour 16 minutes

Janux Therapeutics, Inc. (JANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.91-0.04 (-0.37%)
At close: 04:00PM EDT
10.91 0.00 (0.00%)
After hours: 04:00PM EDT

Janux Therapeutics, Inc.

11099 North Torrey Pines Road
Suite 290
La Jolla, CA 92037
United States
858 750 4700
https://www.januxrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Dr. David Alan Campbell Ph.D.Pres, CEO & Director688.58kN/A1960
Dr. Shahram Salek-Ardakani Ph.D.Chief Scientific Officer371.21kN/A1974
Dr. Wayne Godfrey M.D.Chief Medical Officer488.39kN/A1961
Mr. Tighe M. Reardon C.F.A., CPA, CPAActing Chief Financial OfficerN/AN/A1977
Mr. Tommy Diraimondo Ph.D.Director of ResearchN/AN/AN/A
Mr. Andy Hollman MeyerChief Bus. OfficerN/AN/A1984
Mr. Charles M. WinterSr. VP of Chemistry, Manufacturing & ControlsN/AN/AN/A
Mr. Byron Robinson J.D., Ph.D.Chief Strategy OfficerN/AN/A1965
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Corporate Governance

Janux Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.